Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells
Our Technology
-
Specific target NOT required
-
No genetic modification
-
No expansion of cells
-
4-hour manufacturing process
-
Scalable, Reliable, Low Risk
Upcoming Milestones
-
TBX-3400 clinical trials
-
Phase 1/2 data for melanoma
-
Phase 1/2 data for solid tumors
-
Efficacy data for hepatitis B and HPV
-
-
Initiation of three additional clinical trials